Julphar is selling its diabetes care subsidiary, Diab Tech LLC, to streamline operations and focus on its core pharmaceutical business.
Information on the Target
The Gulf Pharmaceutical Industries, commonly known as Julphar, is one of the largest pharmaceutical manufacturers in the Middle East and Africa. With a significant footprint in the region, Julphar specializes in the production of generic medicines as well as specific therapeutic solutions targeting chronic diseases, including diabetes. The company is headquartered in Ras Al Khaimah, United Arab Emirates, and has established itself as a key player in the healthcare landscape through various innovative drug formulations and manufacturing capabilities.
Recently, Julphar has decided to divest from its subsidiary, Diab Tech LLC, which focuses on diabetes care solutions. This strategic decision forms part of Julphar’s broader aim to consolidate its operations and enhance its core competencies in the pharmaceutical sector, allowing it to focus on its primary business areas.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target’s Specific Country
The pharmaceutical industry in the United Arab Emirates is rapidly growing, supported by increasing healthcare expenditure and a rising prevalence of lifestyle diseases, including di
Similar Deals
IVI-RMA Global → Art Fertility Clinics
GENEO Capital Entrepreneur → Seiven
2025
General Atlantic → Legent Health
2025
ChristianaCare → Crozer Health outpatient locations
2025
Long-time owner of senior living communities → American House Bluewater Bay
2025
N/A
invested in
دياب تك ذ.م.م
in 2024
in a Other Private Equity deal
Disclosed details
Revenue: $122M